Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2 - PubMed (original) (raw)

doi: 10.1016/j.ccr.2004.09.030.

Hosung Min, Juan Leal, Dongyin Yu, Shashirekha Rao, Edward You, Xiu Tang, Haejin Kim, Susanne Meyer, Seog Joon Han, Nessa Hawkins, Robert Rosenfeld, Elyse Davy, Kevin Graham, Frederick Jacobsen, Shirley Stevenson, Joanne Ho, Qing Chen, Thomas Hartmann, Mark Michaels, Michael Kelley, Luke Li, Karen Sitney, Frank Martin, Ji-Rong Sun, Nancy Zhang, John Lu, Juan Estrada, Rakesh Kumar, Angela Coxon, Stephen Kaufman, James Pretorius, Sheila Scully, Russ Cattley, Marc Payton, Steve Coats, Linh Nguyen, Binodh Desilva, Anthony Ndifor, Isaac Hayward, Robert Radinsky, Tom Boone, Richard Kendall

Affiliations

Free article

Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2

Jonathan Oliner et al. Cancer Cell. 2004 Nov.

Free article

Abstract

Angiopoietin-2 (Ang2) exhibits broad expression in the remodeling vasculature of human tumors but very limited expression in normal tissues, making it an attractive candidate target for antiangiogenic cancer therapy. To investigate the functional consequences of blocking Ang2 activity, we generated antibodies and peptide-Fc fusion proteins that potently and selectively neutralize the interaction between Ang2 and its receptor, Tie2. Systemic treatment of tumor-bearing mice with these Ang2-blocking agents resulted in tumor stasis, followed by elimination of all measurable tumor in a subset of animals. These effects were accompanied by reduced endothelial cell proliferation, consistent with an antiangiogenic therapeutic mechanism. Anti-Ang2 therapy also prevented VEGF-stimulated neovascularization in a rat corneal model of angiogenesis. These results imply that specific Ang2 inhibition may represent an effective antiangiogenic strategy for treating patients with solid tumors.

PubMed Disclaimer

Similar articles

Cited by

MeSH terms

Substances

LinkOut - more resources